CAMBRIDGE, Mass., Aug. 8, 2017 /PRNewswire/ -- TCR2 Therapeutics Inc. announced today that its Chief Executive
About TCR2 TherapeuticsTCR2 Therapeutics is an immuno-oncology company that has pioneered a novel class of T cell therapies that utilize the full signaling power of complete T cell receptors (TCR). TCR2 has developed a unique proprietary TRuC™ platform which can reprogram the natural TCR complex to recognize specific antigens found on tumors where they elicit rapid killing of cancer cells. The company has demonstrated superior activity against both hematological and solid tumor targets in preclinical models compared to CAR-T and believes its TRuC™-reprogrammed T cells will serve as a backbone for solid tumor therapies. TCR2 was founded in 2015 by Dr. Patrick Baeuerle and backed with a $44.5M Series A financing led by MPM Capital and F2 Ventures. It has since assembled a world-class team of immunotherapy experts and entrepreneurs located in the heart of Kendall Square in Cambridge, MA. For more information, please visit www.tcr2.com.
View original content:http://www.prnewswire.com/news-releases/tcr2-therapeutics-to-present-at-the-2017-wedbush-pacgrow-healthcare-conference-300500625.html
SOURCE TCR2 Therapeutics
Subscribe to our Free Newsletters!
A prosthetic heart valve is an artificial device surgically implanted into the heart to replace a ...
PUVA or photochemotherapy is used to treat several skin disorders with the help of UV light and the ...
Breathing in unclean air due to increasing air pollution could cause kidney damage with resultant ...View All